Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

February 05, 2013; 80 (6) Article

A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury

Diana D. Cardenas, Edward C. Nieshoff, Kota Suda, Shin-ichi Goto, Luis Sanin, Takehiko Kaneko, Jonathan Sporn, Bruce Parsons, Matt Soulsby, Ruoyong Yang, Ed Whalen, Joseph M. Scavone, Makoto M. Suzuki, Lloyd E. Knapp
First published January 23, 2013, DOI: https://doi.org/10.1212/WNL.0b013e318281546b
Diana D. Cardenas
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward C. Nieshoff
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kota Suda
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shin-ichi Goto
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Sanin
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takehiko Kaneko
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Sporn
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Parsons
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matt Soulsby
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruoyong Yang
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ed Whalen
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph M. Scavone
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makoto M. Suzuki
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lloyd E. Knapp
From the Department of Rehabilitation Medicine (D.D.C.), The Leonard M. Miller School of Medicine, University of Miami, FL; Wayne State University (E.C.N.), Detroit, MI; Pfizer Inc. (L.S., J.S., B.P., R.Y., E.W.), New York; Hokkaido Chuo Rosai Hospital Spinal Cord Injury Center (K.S.), Bibai, Hokkaido; Senboku Kumiai General Hospital (S.G.), Daisen, Akita, Japan; Pfizer Japan (T.K., M.S.), Shibuya-ku, Tokyo; UBC Scientific Solutions (M.S.), Southport, CT; and Pfizer Inc. (J.M.S., L.E.K.), Groton, CT.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury
Diana D. Cardenas, Edward C. Nieshoff, Kota Suda, Shin-ichi Goto, Luis Sanin, Takehiko Kaneko, Jonathan Sporn, Bruce Parsons, Matt Soulsby, Ruoyong Yang, Ed Whalen, Joseph M. Scavone, Makoto M. Suzuki, Lloyd E. Knapp
Neurology Feb 2013, 80 (6) 533-539; DOI: 10.1212/WNL.0b013e318281546b

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1920

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: To assess the efficacy and tolerability of pregabalin for the treatment of central neuropathic pain after spinal cord injury (SCI).

Methods: Patients with chronic, below-level, neuropathic pain due to SCI were randomized to receive 150 to 600 mg/d pregabalin (n = 108) or matching placebo (n = 112) for 17 weeks. Pain was classified in relation to the neurologic level of injury, defined as the most caudal spinal cord segment with normal sensory and motor function, as above, at, or below level. The primary outcome measure was duration-adjusted average change in pain. Key secondary outcome measures included the change in mean pain score from baseline to end point, the percentage of patients with ≥30% reduction in mean pain score at end point, Patient Global Impression of Change scores at end point, and the change in mean pain-related sleep interference score from baseline to end point. Additional outcome measures included the Medical Outcomes Study–Sleep Scale and the Hospital Anxiety and Depression Scale.

Results: Pregabalin treatment resulted in statistically significant improvements over placebo for all primary and key secondary outcome measures. Significant pain improvement was evident as early as week 1 and was sustained throughout the treatment period. Adverse events were consistent with the known safety profile of pregabalin and were mostly mild to moderate in severity. Somnolence and dizziness were most frequently reported.

Conclusions: This study demonstrates that pregabalin is effective and well tolerated in patients with neuropathic pain due to SCI.

Classification of evidence: This study provides Class I evidence that pregabalin, 150 to 600 mg/d, is effective in reducing duration-adjusted average change in pain compared with baseline in patients with SCI over a 16-week period (p = 0.003, 95% confidence interval = −0.98, −0.20).

GLOSSARY

AE=
adverse event;
ANCOVA=
analysis of covariance;
BOCF=
baseline observation carried forward;
CI=
confidence interval;
DAAC=
duration-adjusted average change;
LOCF=
last observation carried forward;
MOS-SS=
Medical Outcomes Study–Sleep Scale;
SCI=
spinal cord injury

Footnotes

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Supplemental data at www.neurology.org

  • Received May 9, 2012.
  • Accepted October 3, 2012.
  • © 2013 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • Warfarin treatment and thrombolysisHow to persuade procrastinators?
  • tPA and warfarinTime to move forward
  • Neighborhood socioeconomic status and stroke mortalityDisentangling individual and area effects
  • The border-land of epilepsy—Revisited
  • Diagnostic shifts in ALS?From clinical specter to imaging spectra
  • Biomarkers for PDHow can we approach complexity?
  • Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS
  • Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease

Topics Discussed

  • Clinical trials Randomized controlled (CONSORT agreement)
  • Neuropathic pain

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise